Table 2 Univariable and multivariable analysis for overall survival of all patients

Presence of CH (VAF ≥ 2.0%)

1.56 (1.07–2.28)

0.020*

1.58 (1.08–2.32)

0.019*

Age (years)

1.02 (1.00–1.04)

0.047*

Sex (male)

1.06 (0.77–1.46)

0.711

History of smoking

1.19 (0.87–1.63)

0.265

The number of comorbidities

 1 vs. 0

0.82 (0.57–1.20)

0.307

0.85 (0.58–1.25)

0.407

 ≥ 2 vs. 0

1.97 (1.36–2.85)

 < 0.001*

1.67 (1.12–2.48)

0.011*

Pulmonary function

 FEV1 < 60%

1.15 (0.54–2.45)

0.722

 DLCO < 60%

1.78 (1.03–3.07)

0.040*

2.22 (1.24–3.96)

0.007*

EGFR mutation

 No vs. yes

2.29 (1.55–3.39)

 < 0.001*

2.41 (1.59–3.65)

 < 0.001*

 Unchecked vs. yes

2.68 (1.83–3.90)

 < 0.001*

3.11 (2.09–4.64)

 < 0.001*

Histologic structure

 SqCC vs. ADC

0.88 (0.61–1.26)

0.482

 Others vs. ADC

1.38 (0.79–2.40)

0.258

Pathological stage

 IIIA vs. IIB

1.83 (1.29–2.58)

0.001*

1.49 (1.01–2.19)

0.045*

 IIIB vs. IIB

2.69 (1.72–4.21)

 < 0.001*

2.18 (1.32–3.60)

0.002*

Adjuvant therapy

 CTx vs. CRTx

0.78 (0.57–1.05)

0.103